Sartorius acquires majority stake in CellGenix

Portfolio expanded by cell culture components, such as growth factors, cytokines, and media

05-Jul-2021 - The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the biotechnology hub in Boston, Massachusetts USA, produces and ...

CellGenix received ISO 9001:2008 certification

18-Jul-2012 - CellGenix’ quality management system was certified in April 2012 on the requirements of DIN EN ISO 9001:2008 standard by the TÜV Rheinland Cert GmbH. To highlight CellGenix’ commitment to quality and service the certification of ISO 9001:2008 covers all relevant functions of the company, ...

CellGenix Technologie Transfer GmbH: 15 Years of Innovation and Leadership

05-May-2009 - 2009 is a special year for CellGenix, according to the company. Cellgenix is celebrating its 15th anniversary. CellGenix was founded in May 1994 as a Spin-off from the University Medical Center Freiburg and has developed continuously ever since. 1997 the company launched the first GMP quality ...

CellGenix registers FDA Drug Master Files for ex-vivo CellGro® TNF-a and GM-CSF

16-Jun-2005 - CellGenix has registered two new drug master files for TNF-a and GM-CSF. After filing a DMF for IL-4, this contributes further to the strategy of producing highest quality cytokines for the use in clinical ex-vivo cell culturing in connection with cell processing kits. As proposed in the new USP ...